Sumitomo Pharma Co., Ltd. (4506.T)
JPY 575.0
(-0.69%)
JPY 575.0
(-0.69%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Revenue | 314.55 Billion | 555.54 Billion | 560.03 Billion | 515.95 Billion | 482.73 Billion | 459.26 Billion |
| Cost of Revenue | 126.57 Billion | 178.91 Billion | 157.12 Billion | 137.77 Billion | 129.67 Billion | 113.55 Billion |
| Gross Profit | 187.98 Billion | 376.62 Billion | 402.9 Billion | 378.17 Billion | 353.05 Billion | 345.71 Billion |
| Operating Expenses | 542.17 Billion | 453.6 Billion | 342.67 Billion | 306.95 Billion | 269.82 Billion | 287.83 Billion |
| Selling, General and Administrative Expenses | 429.53 Billion | 373.31 Billion | 249.08 Billion | 190.37 Billion | 154.34 Billion | 180.43 Billion |
| Research and Development Expenses | 112.63 Billion | 131.85 Billion | 94.9 Billion | 132.68 Billion | 115.11 Billion | 102.36 Billion |
| Other Expenses | - | - | -1.31 Billion | -16.1 Billion | 360 Million | 5.02 Billion |
| Cost and Expenses | 669.41 Billion | 632.52 Billion | 499.8 Billion | 444.72 Billion | 399.49 Billion | 401.38 Billion |
| Operating Income | -354.19 Billion | -76.97 Billion | 60.23 Billion | 71.22 Billion | 83.23 Billion | 57.88 Billion |
| Interest Expense | 4.27 Billion | 3.15 Billion | 3.05 Billion | 2.58 Billion | 2.86 Billion | 207 Million |
| Income Tax Expense | -8.18 Billion | 48.79 Billion | 42.36 Billion | 41.02 Billion | 48.02 Billion | 16.41 Billion |
| Earnings before Tax | -323.11 Billion | -47.92 Billion | 82.96 Billion | 77.85 Billion | 83.94 Billion | 65.04 Billion |
| Net Income | -314.96 Billion | -74.51 Billion | 56.41 Billion | 56.21 Billion | 40.75 Billion | 48.62 Billion |
| Earnings Per Share Basic | -792.79 | -187.55 | 141.99 | 141.50 | 102.58 | 122.39 |
| Earnings Per Share Diluted | -792.79 | -187.55 | 141.99 | 141.50 | 102.58 | 122.39 |
| Weighted Average Shares Outstanding | 397.29 Million | 397.29 Million | 397.29 Million | 397.29 Million | 397.29 Million | 397.29 Million |
| Weighted Average Shares Outstanding (Diluted) | 397.29 Million | 397.29 Million | 397.29 Million | 397.29 Million | 397.29 Million | 397.29 Million |
| Gross Margin | 0.60 | 0.68 | 0.72 | 0.73 | 0.73 | 0.75 |
| EBIT Margin | -0.89 | -0.01 | 0.22 | 0.20 | 0.22 | 0.17 |
| Profit Margin | -1.00 | -0.13 | 0.10 | 0.11 | 0.08 | 0.11 |
| EBITDA | -281.07 Billion | -3.49 Billion | 124.35 Billion | 103.11 Billion | 100.28 Billion | 79.22 Billion |
| Earnings Before Tax Margin | -1.13 | -0.14 | 0.11 | 0.14 | 0.17 | 0.13 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 90.07 Billion | 90.67 Billion | 314.55 Billion | 79.53 Billion | 82.38 Billion | 76.95 Billion |
| Cost of Revenue | 37.37 Billion | 34.94 Billion | 126.57 Billion | 33.38 Billion | 32.86 Billion | 29.89 Billion |
| Gross Profit | 52.69 Billion | 55.72 Billion | 187.98 Billion | 46.14 Billion | 49.51 Billion | 47.06 Billion |
| Operating Expenses | 57.78 Billion | 58.83 Billion | 542.17 Billion | 276.97 Billion | 80.76 Billion | 81.99 Billion |
| Selling, General and Administrative Expenses | 44.63 Billion | 45.35 Billion | - | 237.98 Billion | 57.51 Billion | 59.15 Billion |
| Research and Development Expenses | 13.14 Billion | 13.12 Billion | - | 38.99 Billion | 23.29 Billion | 22.51 Billion |
| Other Expenses | - | - | - | - | - | - |
| Cost and Expenses | 95.16 Billion | 93.78 Billion | 668.75 Billion | 310.35 Billion | 113.63 Billion | 111.88 Billion |
| Operating Income | -5.09 Billion | -3.1 Billion | -354.19 Billion | -230.82 Billion | -31.24 Billion | -34.93 Billion |
| Interest Expense | 23.4 Billion | 2.02 Billion | 4.27 Billion | 1.54 Billion | 17.81 Billion | 851 Million |
| Income Tax Expense | -1.44 Billion | 1.26 Billion | -8.18 Billion | -20.69 Billion | 899 Million | 3.79 Billion |
| Earnings before Tax | -49.6 Billion | 17.2 Billion | -323.11 Billion | -217.92 Billion | -49.06 Billion | -25.07 Billion |
| Net Income | -48.16 Billion | 15.93 Billion | -314.96 Billion | -197.26 Billion | -49.96 Billion | -28.87 Billion |
| Earnings Per Share Basic | -121.24 | 40.11 | - | -496.52 | -125.77 | -72.68 |
| Earnings Per Share Diluted | -121.24 | 40.11 | - | -496.52 | -125.77 | -72.68 |
| Weighted Average Shares Outstanding | 397.29 Million | 397.29 Million | 397.29 Million | 397.29 Million | 397.29 Million | 397.29 Million |
| Weighted Average Shares Outstanding (Diluted) | 397.29 Million | 397.29 Million | 397.29 Million | 397.29 Million | 397.29 Million | 397.29 Million |
| Gross Margin | 0.59 | 0.61 | 0.60 | 0.58 | 0.60 | 0.61 |
| EBIT Margin | 0.02 | 0.04 | - | -2.78 | -0.26 | -0.19 |
| Profit Margin | -0.53 | 0.18 | -1.00 | -2.48 | -0.61 | -0.38 |
| EBITDA | 1.7 Billion | 3.8 Billion | - | -221.32 Billion | -21.64 Billion | -14.78 Billion |
| Earnings Before Tax Margin | -0.06 | -0.03 | -1.13 | -2.90 | -0.38 | -0.45 |
1376
TRANSFRE
EMMESSA
3353
VIVHY
FCAFF